Kymera Therapeutics, Inc. reported $105M of revenue over the trailing twelve months, +135% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $105M (to Q2 2026). Net income: −$300M, trailing twelve months to Q2 2026. Free cash flow: −$238M, trailing twelve months to Q2 2026. Operating margin: −1780%, trailing twelve months to Q2 2026.

KYMRKymera Therapeutics, Inc.

Healthcare

$112.32+129% 1Y

$112.32

$50.8752 weeks$127.24

KYMR as reported

Kymera Therapeutics, Inc. reported $105M of revenue over the trailing twelve months, +135% on the year before. 9 reported series are charted on this page, each one as filed.

$105M

Revenue, trailing twelve months · to Q2 2026 · +135% against the twelve months before

Net income: −$300M
Net income · +8.8% year on year · trailing twelve months to Q2 2026
Free cash flow: −$238M
Free cash flow · −6.1% year on year · trailing twelve months to Q2 2026
Operating margin: −1780%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for KYMR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$105M	+135%	Q2 2026
Net income	−$300M	+8.8%	Q2 2026
EPS	−$3.25	−6.6%	Q2 2026
Gross margin	0.00%	n/a	Q2 2026
Operating margin	−1780%	n/a	Q2 2026
Net margin	−1575%	n/a	Q2 2026
ROE	−23%	n/a	Q2 2026
ROA	−20%	n/a	Q2 2026
Free cash flow	−$238M	−6.1%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.